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esponsibility of InstAbstract The drug metabolism is a biochemical process on modiﬁcation of pharmaceutical substances
through specialized enzymatic systems. Changes in the expression of drug-metabolizing enzyme genes
can affect drug metabolism. Recently, epigenetic regulation of drug-metabolizing enzyme genes has
emerged as an important mechanism. Epigenetic regulation refers to heritable factors of genomic
modiﬁcations that do not involve changes in DNA sequence. Examples of such modiﬁcations include
DNA methylation, histone modiﬁcations, and non-coding RNAs. This review examines the widespread
effect of epigenetic regulations on genes involved in drug metabolism, and also suggests a network
perspective of epigenetic regulation. The epigenetic mechanisms have important clinical implications and
may provide insights into effective drug development and improve safety of drug therapy.
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Drug metabolism is the biotransformation process of pharmaceutical
substances or xenobiotics, usually conducted by specialized enzymatic
systems. Drug metabolism is divided into three phases. Phase-I
contains the modiﬁcation reactions of oxidation, reduction, and
hydrolysis. Typical examples of phase-I enzymes include cytochrome
P450s (P450s), ﬂavin monooxygenases (FMOs), alcohol dehydro-
genases (ADHs), aldehyde dehydrogenases (ALDHs), cytochrome
P450 oxidoreductase (POR), aldo-keto reductase (AKR), quinone
oxidoreductase (NQO), dihydropyrimidine dehydrogenase (DPYD),
carboxylesterase (CES), paraoxonase (PON), and epoxide hydrolase
(EPHX). Phase-II consists of conjugation reactions usually catalyzed
by transferase enzymes, such as UDP-glucuronosyltransferases
(UGTs), sulfotransferases (SULTs), glutathione S-transferases (GSTs),
N-acetyltransferases (NATs), thiopurine methyltransferase (TPMT),
catechol-O-methyl transferase (COMT). Phase-III is the uptake and
excretion process of drugs and their metabolites through transporters. In
a coordinated fashion to transport endogenous and exogenous sub-
stances into and out of cells, transporters can be divided into two
groups: uptake and efﬂux transporters. Major drug transporters include
solute carrier transporters (SLCs) and ATP-binding cassette transporters
(ABCs). The function of enzymes and transporters involved in the
three phases determines the duration and intensity of a drug's effect.
Factors inﬂuencing the expression and function of drug-
metabolizing enzymes and transporters are critical to the metabolic
process and therapeutic outcome of a drug. It is well known
that genetic variations of enzymes and transporters can lead to
altered drug response. Many genetic polymorphisms in genes
encoding drug-metabolizing enzymes and transporters have been
identiﬁed1,2, which can be translated into clinical differences.
However, the large interindividual variations in drug response can
only be partly explained by genetic factors. For most cases, only
10%–30% of phenotype variations can be explained by genetic
polymorphisms in genes encoding drug-metabolizing enzymes and
transporters3. The genetic information can be differentially
expressed in one individual over time and space, and even
monozygotic twins do not always show the same phenotype, so
epigenetic factors are now considered as an important part of the
molecular control for gene expression4. In this review, the general
concept of epigenetics will be brieﬂy introduced, and its regulation
on genes encoding proteins involved in drug metabolism and
transport will be overviewed. We will also examine the epigenetic
mechanisms as a regulatory network and discuss the implications
of epigenetic research on pharmacotherapy.2. Property of epigenetics
Epigenetics studies heritable changes in gene expression that are
not caused by alterations in DNA sequences. Epigenetic regulation
leads to relatively stable changes that are potentially affected by
many other factors, such as age, diet, life style, disease and
environment. Several mechanisms of epigenetic regulation have
been extensively studied, including DNA methylation, histone
modiﬁcations, and non-coding RNAs, each of which can change
gene expression without altering the underlying DNA sequences.
2.1. DNA methylation
DNA methylation usually refers to the addition of a methyl group
to the cytosine pyrimidine ring at the 5 position in a CpGdinucleotide context. Status of DNA methylation on a CpG site
is maintained by DNA methyltransferases (DNMTs) and demethy-
lases and can be inherited through cell divisions. DNA methylation
is necessary for proper gene regulation, chromosomal stability, and
parental imprinting5. It plays an important role in long-term
silencing of transcription and in heterochromatin formation. One
way DNA methylation can silence transcription is that it directly
alters chromatin structure and prohibits the binding of transcription
factors or co-activators to their targeted sites containing this
modiﬁcation, and therefore decreases the gene expression. DNA
methylation may also recruit methyl binding proteins (MBPs) that
interact with co-repressors and lead to an inactive chromatin
status6,7.2.2. Histone modiﬁcations
Histone proteins in the nucleosome, surrounded by 146 bp DNA,
play a dominant role in the regulation of gene expression. Several
covalent modiﬁcations on the N-termini of histone proteins have
been discovered, many of which contain distinct regulatory
functions and are transmissible through cell divisions8. Histone
modiﬁcations can be divided into those that correlate with
activation or repression of gene expression. Histone H3 acetylation
is an important epigenetic modiﬁcation regarding the ability for
genes to be transcribed. Acetylation has the most potential to
unfold chromatin, because it neutralizes the basic charge of the
lysine residual and loosens the interaction between histone and
DNA. Acetylation is generally associated with activation of
transcription. Several histone acetyltransferases (HATs) have been
identiﬁed as transcription co-activators. In contrast, histone de-
acetylation is generally associated with repression of transcription.
Histone deacetylases (HDACs) have been identiﬁed as transcrip-
tional co-repressors9.
Methylation of histone by methyltransferases can lead to
different effects on gene transcription, depending on which
residual is methylated and the level of methylation (mono-, di-,
tri-methylation) occurs10. By analyzing the chromatin landmark
and transcription initiation at most promoters in human ES cells,
three classes of genes with various histone methylations have been
identiﬁed11. The majority of actively transcribed genes have
H3K4me2/3-modiﬁed nucleosomes around the transcription start
sites (TSS), and H3K36me3 along the gene-coding regions after
TSSs. Certain genes do not have H3K4me2/3-modiﬁed nucleo-
somes around their TSS; some of them are enriched with
H3K27me3 along the genes. A ChIP-on-chip study demonstrates
that H3K27me3 forms broad local enrichments over silent genes
and intergenic regions on gene-rich regions on mouse chromo-
somes12. Vast data have conﬁrmed that H3K4me3 and H3K4me2
are related to initiation of gene transcription, H3K36me3 is
correlated to elongation of gene transcription, whereas
H3K27me3 is associated with suppression of gene transcrip-
tion10,13–18. Although both H3K4me3 and H3K4me2 are asso-
ciated with activation of transcription initiation, H3K4me3 is
enriched more frequently around TSSs of genes, whereas
H3K4me2 is found in a broader range of promoters, enhancers,
and long-range regulatory elements. H3K4me2 sites also have a
higher degree than H3K4me3 to associate with tissue-speciﬁc gene
regulation13. Interestingly, the co-occurrence between histone
acetylation of H3K9/H3K14 and methylation of H3K4 is very
high for actively transcribed genes13,19. One of the reasons may be
that the complex of general transcription factors is selectively
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general transcription factors to methylated H3K4 is enhanced by
coincident H3K9 and H3K14 acetylation20. Methylation and
demethylation of H3K4, H3K36, and H3K27 serve as a “multi-
stable-switch” model of epigenetic memory to control gene
expression in cellular differentiation and development21. With a
widespread in chromatin, H3K9me2 is frequently associated with
DNA methylation and is both a repressive mark in euchromatin
and a hallmark of heterochromatin22–24. H3K9me2 associated
genes are enriched in many tightly-controlled signaling and cell-
type speciﬁc pathways25. Approximately 46% of mouse genome is
covered by H3K9me2 in adult liver, and large H3K9me2-modiﬁed
DNA regions are associated with tissue-speciﬁc gene silencing in
differentiated tissues26. There is little overlap between H3K9me2
and H3K27me3 in mouse liver26, indicating a unique and essential
role of H3K9me2 in epigenetic control of tissue-speciﬁc gene
expression. In liver, H3K9me2 mediates gene repression by small
heterodimer partner (SHP)27,28, an orphan nuclear receptor that
inhibits the transcriptional activities of many nuclear receptors29,30.
H3K4me2 and H3K9me2 inhibit each other in vitro31, and
increase and decrease of H3K4me2 and H3K9me2 correlate with
up- and down-regulation of genes by ethanol in hepatocytes32.
2.3. Non-coding RNAs (ncRNAs)
ncRNAs are functional RNA molecules that are not translated into
proteins. More and more researches have focused on the regulatory
function of ncRNAs. The best characterized ncRNAs are a group
of small ncRNAs, the microRNAs (miRNAs), which regulate the
expression of protein-coding genes. Matured miRNAs contain
approximately 22 nucleotides, and they can base-pair with
complementary sequences usually located in the 30 untranslated
region (UTR) of the targeted mRNA molecules. This interaction
either promotes destabilization and degradation of the mRNAs, or
leads to decreased translational efﬁciency to achieve the gene
silencing effect of miRNAs33. Recent studies have also identiﬁed
the role of miRNAs in cellular memory and epigenetics34. Long
non-coding RNAs (lncRNAs) are generally deﬁned as non-protein
coding transcripts with longer than 200 nucleotides. lncRNAs have
been discovered to perform regulatory functions in various
biological processes, including cell cycle, pluripotency, cell
differentiation and development, due to its special property to
interact with both DNAs and proteins35,36. Although conceptually
not epigenetic marks, ncRNAs are an integrated part of epigenetic
regulation whereby relevant ncRNAs contribute to the ﬁnal
transcriptional outcome of protein-coding genes without genetic
alterations37.3. Epigenetic regulation of genes involved in drug metabolism
and transport
Several full lists of drug metabolism and transport genes under
epigenetic regulation have been summarized37–39. This review is
not attempting to make a comprehensive coverage on this topic,
but rather a personal selection of epigenetic interplay with drug
metabolism that is exciting and promising for the future.
DNA methylation is perhaps the best known epigenetic process,
and up to date approximately 90% of identiﬁed epigenetic
regulation in drug-metabolizing genes involve DNA methylation.
One of the major reasons is that aberrant DNA methylation is a
hallmark of cancer. The disease of cancer has been intensivelystudied, and changes of drug-metabolizing gene expression
associated with altered DNA methylation in various tumor cells
have been well identiﬁed. Examples of drug-metabolizing genes
regulated by cancer-related DNA methylations occur in all three
phases of drug metabolism, including phase-I enzymes, such as
CYP1A140 and CYP7B141, phase-II enzymes, such as
SULT1A142 and NAT143, and phase-III transporters, such as
ABCC644 and SLC22A345. Some genes display reduced expres-
sion and are hypermethylated at promoter regions in different
tumor cells, like ALDH1A246 and CYP2447. On the other hand,
several transporters showed increased expression that correlates
promoter hypomethylation in certain tumor cells, like SLC19A148
and ABCG249, leading to drug resistance phenotype of cancers.
Besides promoter regions, cancer-related changes in enhancer
methylation have been shown to alter the induction of drug-
metabolizing genes. For example, enhancer hypermethylation
suppresses CYP1A1 dioxin responsiveness in prostate cancer50.
In addition to cancer, many other situations can lead to altered
DNA methylations that regulate drug-metabolizing gene expres-
sion. Parkinson's disease may be associated with epigenetic
modiﬁcations, and decreased DNA methylation in the gene region
was linked to increased expression of CYP2E1 in the brains of
Parkinson's disease patients51. Differences in life style may affect
epigenetics. For instance, tobacco smoking was associated with
hypomethylation of CYP1A1 and may be involved in the induction
of CYP1A1 in the lung52. Differences in diet may also regulate
drug-metabolizing genes through DNA methylation. Prenatal
famine has been linked to timing- and sex-speciﬁc alteration of
DNA methylations in ABCA1 gene53. Moreover, DNA methyla-
tion is implicated in tissue speciﬁc gene expression. For example,
the promoter CpG methylation status of CYP1A2 was strongly
associated with CYP1A2 mRNA expression in different human cell
lines and tissues12. The CpG-rich region near the UGT1A1
promoter was hypermethylated in the kidney, and UGT1A1
expression was defective in human kidney54. The variable level
of CYP2E1 RNA in full-term placenta was associated with a DNA
methylation pattern distinct from other tissues55.
Although DNA methylation is the most common epigenetic
mechanism of mammalian genome regulation, it is only one
component of a broad epigenetic program that includes other
modiﬁcations of the chromatin. Histone acetylation is an epige-
netic modiﬁcation that shows close crosstalk with DNA methyla-
tion. The methyl-CpG domain binding protein MeCP2 and MBD2
were found to be associated with HDAC5, and increased histone
acetylation by HDAC inhibitor induced global DNA demethyla-
tion in human cancer cells56. Therefore, DNA methylation con-
trolled drug-metabolizing gene expressions are commonly coupled
with changes in histone acetylation57. For example, both histone
hyperacetylation and DNA hypomethylation contributed to the
tissue speciﬁc expression of UGT1A1 in the liver and intestine54;
inhibitor treatment to decrease histone deacetylation and DNA
methylation induced CYP1 family RNA expression in MCF-7 and
Hela cells58; the suppression of CYP27B1 by the ligand-activated
vitamin D receptor was mediated through dual epigenetic modi-
ﬁcations—DNA methylation and recruitment of histone deacety-
lase59. With the help of histone acetylation modulating molecules,
typically histone deacetylase inhibitors, histone acetylation is also
demonstrated to be involved in regulation of drug-metabolizing
genes in all three phases, examples of which include phase-I
CYP3A460, phase-II UGT2B761, and phase-III SLC22A262.
Histone methylation is another important epigenetic mechanism
in regulation of drug-metabolizing genes. In some cases, histone
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tions. The repression of CYP24A1 gene expression in human
prostate cancer cells was mediated by increased promoter DNA
methylation and repressive histone mark H3K9me2, together with
decreased histone H3K9ac and H3K4me2 modiﬁcation63. In other
cases, histone modiﬁcations can work independently to silence
gene transcription in the absence of DNA methylation. The
knockdown of retinoic acid receptors in embryo carcinoma cell
lines led to CYP26A1 repression through increased level of
repressive histone mark H3K9 methylation and hypoacetylation
of histone H4 without changes in DNA methylation64.
Histone modiﬁcations play a role in drug-metabolizing gene
regulation in response to nuclear receptor ligand treatment. The
induction of CYP1A1 through aryl hydrocarbon receptor activa-
tion involved increased active histone mark of H3K4me3 at the
gene promoter and increased histone acetylation at both the
promoter and enhancer region65. Histone methylation may also
function in developmental regulation of drug-metabolizing gene
expression. The increases of CYP3A16 expression in neonatal
mouse livers and CYP3A11 in adult livers were associated with
increase of active histone mark H3K4me2, while the suppression
of CYP3A16 expression in adult livers coincided with the decrease
of H3K4me2 and increase of inactive mark H3K27me3 around
Cyp3a1666. Neonatal activation of the nuclear receptor CAR by a
CAR-speciﬁc ligand (1,4-bis[2-(3,5-dichloropyridyloxy)]benzene,
TCPOBOP) can result in alteration of H3K4me3 and H3K9me3
levels around the CAR targeted drug-metabolizing genes, Cyp2b10
and Cyp2c37, which further results in an induced expression level of
these P450s throughout the life of exposed mice67.
Different from the above epigenetic mechanisms, miRNAs
affect drug-metabolizing gene expression at the post-
transcriptional stage rather than transcriptional regulation. Similar
to DNA methylations, alterations of miRNAs are common in
cancer. And many of them were initially studied in the regulation
of key cancer-related pathways, such as cell cycle control and the
DNA damage response68. The ﬁrst study that demonstrated
miRNAs in regulation of essential genes in physiology and drug
metabolism was on miR-27b and CYP1B1 in cancerous tissues,
which identiﬁed a signiﬁcant inverse association between the
expression levels of miR-27b and CYP1B1 protein69. Following
this, many other miRNAs were also found in regulating drug-
metabolizing genes. The CYP2E1 mRNA and protein levels
showed no positive correlation in human liver samples, suggesting
post-transcriptional regulation. The miR-378 was reported to
potentially recognize the 30-UTR of CYP2E1 mRNA by in silico
analysis, and its level was inversely correlated with the CYP2E1
protein level and translational efﬁciency of CYP2E1, which
provided insight into the unsolved post-transcriptional regulatory
mechanism70. Another special property of miRNA differing from
other cis-regulating epigenetic marks is that it can perform the
regulatory function in trans and therefore interact with multiple
targets. The human miR-27b not only directly targeted the 30-UTR
of CYP3A4 to down-regulate CYP3A4 level through post-
transcriptional mechanism, but also targeted the 30-UTR of
vitamin D receptor, which indirectly control CYP3A4 expression
through transcriptional regulation71. In addition to the above
phase-I genes, miRNAs were also identiﬁed in regulation of
phase-II enzymes and transporters. For example, the UGT1A gene
family was regulated by miR-491-3p, which binds to the shared
UGT1A 30-UTR common to all UGT1A enzymes. And altered
miRNA levels showed an inverse correlation with UGT1A mRNA
level and enzyme activity both in vitro and in vivo72. TransporterABCG2 protein expression could be affected by multiple miRNAs,
including miR-328, -519c, and -520h, probably through accelerated
mRNA degradation mechanism73.
Evidences of epigenetic regulation of expression involving
lncRNAs have been discovered in many genes. Some well-
known cases include the lncRNA Xist mediated X-chromosome
inactivation and Air mediated Igf2r gene imprinting74. However,
ﬁndings about drug-metabolizing gene regulation are quite limited.
Transporters Slc22a2 and Slc22a3 are located in the Igf2r gene
cluster, and thus are also silenced by Air during imprinting. One
example of lncRNA regulating drug-metabolizing gene in human
is related to the short-chain dehydrogenase/reductase family
member 4 (DHRS4) gene cluster75. The lncRNA AS1DHRS4, a
natural antisense transcript of the DHRS4 gene, could either recruit
DNA methyltransferases to induce DNA methylation or interact
with H3K9 and H3K27 methyltransferases to maintain epigenetic
silencing in the DHRS4 gene cluster. Most chromatin modifying
enzymes do not have the capacity to bind DNA, and lncRNAs
usually bridge the gap and precisely target proteins to DNA.4. Epigenetic network
Epigenetic mechanism has been universally accepted as a critical
factor in gene regulation, and its general role can be applied to
almost every genes in the genome, including the ﬁeld of drug
metabolism, as reﬂected by the numerous examples summarized
above. However, most of the current studies have only identiﬁed
the involvement of certain epigenetic elements in gene regulation,
revealing the association of altered epigenetic modiﬁcations with
changes of gene expression, yet a bigger scenario of how these
epigenetic modiﬁcations occur is not well understood. The
universal role of epigenetic mechanism involved in gene regula-
tion strongly indicates that epigenetics is an executor rather than an
initiator in control of gene expression. Epigenetic regulations are
not proactive, but responsive. They commonly happen in response
to changes of environment, diet, physiological or pathological
conditions. The inheritance of epigenetics simply memorizes what
has been set up by other cellular mechanisms or pathways.
Moreover, the known examples also suggest that there are
interactions between different epigenetic modiﬁcations, either
mutually reinforced or inhibitory. Thus, understanding the cellular
regulatory network that depicted the epigenetic modiﬁcations
would be more rewarding in the study of gene regulation. We
have recognized the association of different epigenetic modiﬁca-
tions with gene expression, but the triggers for the differential
marking of epigenetic modiﬁcations throughout the genome is
largely unclear. Epigenetic modiﬁcations are like the “code” that
control gene expression levels, yet from a network view, there
must be “pens” that write down the “code” and “writers” that hold
the “pens”. For instance, Pozzi et al.64 demonstrated that retinoic
acid (RA) induced epigenetic activation of CYP26A1 required the
activity of RARβ2, which was further activated by functional
RARα in response to RA. Future researches investigating the
coordinated network involving chains of signaling upstream of the
epigenetic codes are essential to unveil the mystery of gene
regulation.
Examining the epigenetic regulation as a network has another
important implication. Various epigenetic enzymes have been
known to modify the epigenetic signature of genes, such as
DNMT, HAT, and HDAC. A number of drugs targeting these
enzymes are under development for treatment of certain diseases,
Figure 1 Schematic illustration of epigenetic regulation on drug metabolism and transport. DNA methylation at CpG sites may alter chromatin
structure and prohibit the binding of transcription factors (TF) or co-activators (CoA) and therefore decrease the gene expression. DNA
methylation may also recruit methyl binding proteins (MBP) that interact with co-repressors (CoR) and lead to decreased gene expression. Histone
acetylation has the potential to unfold chromatin and may activate gene expression. Histone methylations can be divided into gene-activating and
gene-repressive histone marks. LncRNAs may interact with epigenetic and basic transcription machinery to alter gene transcription. microRNAs
can decrease the mRNA stability or inhibit translation through binding with mRNAs. All of these epigenetic factors targeting drug-metabolizing
enzyme genes and transporter genes may lead to altered drug metabolism and transport.
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But most of the epigenetic drugs have strong toxic effects due to
lack of speciﬁcity. The modifying enzymes modulate epigenetic
signatures all over the genome, yet most disease-related epigenetic
changes only occur locally. So improved understanding of the
epigenetic regulatory network may suggest new drug targets with
better speciﬁcity and provide novel insight into drug discovery and
development. Furthermore, altered drug-metabolizing gene expres-
sions are often linked to drug efﬁcacy and safety issues. The study
of epigenetic regulatory pathways in drug-metabolizing enzymes
and transporters may facilitate the understanding of drug-drug
interactions and multi-drug resistance in clinical pharmacotherapy.5. Clinical signiﬁcance of epigenetic mechanisms in
regulation of drug metabolism
It has been clearly demonstrated that epigenetic mechanisms
contribute to the differential expression of drug-metabolizing
genes in various situations. One important thing to infer from this
is that we should be cautious about the epigenetic property of
drugs, which may affect drug-metabolizing gene expression and
drug disposition. Certain compounds with epigenetic modulating
capacities are helpful in research, such as DNMT inhibitor 5-aza-
20-deoxycytidine to decrease DNA methylation and HDAC
inhibitor trichostatin A to increase histone acetylation76. Treatment
experiments with these compounds have aided in the identiﬁcation
and validation of epigenetic regulation in a large number of drug-
metabolizing genes. Yet some clinically used drugs may also have
the property to alter epigenetic signatures of drug-metabolizing
genes, and lead to unexpected changes in drug metabolism and
toxicity. For example, the anticonvulsant and mood-stabilizing
drug valproic acid has been discovered as histone deacetylase
inhibitor with potent antitumor activity77. So potential changes in
the expression of drug-metabolizing genes under epigenetic
regulation may also need to be taken into consideration when this
kind of epigenetic drug is administered.6. Conclusions
In summary, epigenetic regulation of drug-metabolizing genes and
transporters is a critical factor in control of drug metabolism and
transport as schematically illustrated in Fig. 1. Epigenetic mecha-
nism is an important source of interindividual variability in drug
metabolism and transport. Combining the current understanding
with further studies about the network of epigenetic regulations in
drug metabolism may help to improve the safety and effectiveness
of drug therapy.Acknowledgments
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